SIADH Clinical Trial
Official title:
Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study
Syndrome of inappropriate antidiuresis (SIADH) is characterized by an imbalance of
antidiuretic vasopressin (AVP) secretion. The impaired AVP regulation leads to water
retention and secondary natriuresis and is a common cause for hyponatremia.
The therapeutic options, aside from treating the underlying disease, depend upon the onset
and severity of the symptoms and involve usually fluid restriction or hypertonic saline
infusion. Alternative therapeutic options are loop diuretics, administration of oral urea or
vasopressin receptor antagonists (vaptans). Despite those options, there are a considerable
number of patients which do not sufficiently respond, making additional therapy necessary.
Empagliflozin (Jardiance)® is a sodium glucose co-transporter 2 (SGLT2)-inhibitor, which is a
new treatment option developed for patients with diabetes mellitus type 2. The SGLT2 is
expressed in the proximal tubule and reabsorbs approximately 90 percent of the filtered
glucose. The inhibition of SGLT2 results in renal excretion of glucose with subsequent
osmotic diuresis. This mechanism could result in a therapeutic effect in patients with
hypotonic hyponatremia as in SIADH.
The aim of this study is to evaluate whether empagliflozin (Jardiance)® has an effect on the
serum sodium levels of patients with SIADH.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05055856 -
Asymptomatic Bacteriuria, Hyponatremia and Geri-atric Syndrome
|
N/A | |
| Active, not recruiting |
NCT01228682 -
Post-Authorisation Safety Study of Samsca (Tolvaptan) Used in Routine Medical Practice
|
N/A | |
| Withdrawn |
NCT01425125 -
Fractional Urate Excretion in Nonedematous Hyponatremia
|
N/A | |
| Recruiting |
NCT06171100 -
Low-dose Tolvaptan for Inpatient Hyponatraemia.
|
||
| Completed |
NCT04744987 -
Changes in Serum Creatinine Levels Can Help Distinguish Hypovolemic From Euvolemic Hyponatremia
|
||
| Active, not recruiting |
NCT04409626 -
Hyponatraemia and Mortality in Schizophrenic and Bipolar Patients: Protocol for a Bayesian Causal Inference Study
|
||
| Recruiting |
NCT04447911 -
Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia
|
Phase 4 | |
| Not yet recruiting |
NCT01509170 -
The Clinical and Laboratory Characteristics of Recurrent Drug- Related Hyponatremia
|
N/A | |
| Recruiting |
NCT04552873 -
Urea Therapy for Hyponatremia in Subarachnoid Hemorrhage
|
N/A | |
| Terminated |
NCT02545114 -
Tolvaptan for Patients With Acute Neurological Injuries
|
N/A |